Advertisement

Search Results

Advertisement



Your search for ASCO Post,ASCO Post matches 16428 pages

Showing 1 - 50


lung cancer

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

On April 18, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor alectinib (Alecensa) for adjuvant treatment after tumor resection in patients with ALK-positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. Alectinib is an orally...

head and neck cancer

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

A novel MDM2 inhibitor has demonstrated antitumor activity in progressive salivary cancer, particularly adenoid cystic carcinoma, according to data presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium. Results of the phase I/II trial showed an overall response rate of 13% and a...

prostate cancer
issues in oncology

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer

A novel single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition method using lead (Pb)-212–prostate-specific membrane antigen (PSMA)-based targeted alpha therapy may provide convenient detection of radiopharmaceutical biodistribution and could lead to improved practice ...

lung cancer
issues in oncology

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society, the Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations on the use of certain...

pancreatic cancer
issues in oncology

Improving Early Detection of Pancreatic Cancer in High-Risk Patients

Researchers have identified a novel strategy to screen for pancreatic cancer in high-risk patients, according to a recent study published by Zogopoulos et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings demonstrated the feasibility of improving the early detection and ...

breast cancer
colorectal cancer
lung cancer
issues in oncology

Survival Rates in Patients With Cancer and Intellectual and Developmental Disabilities

Investigators have found a higher rate of mortality among patients with intellectual and developmental disabilities diagnosed with breast cancer, colorectal cancer, or lung cancer, according to a recent study published by Hansford et al in the Canadian Journal of Public Health. Study Methods and...

multiple myeloma

Natalie S. Callander, MD, on Multiple Myeloma: Management Updates

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses advances in the treatment of patients with multiple myeloma, including her commentary on smoldering disease, the early use of CAR T-cell therapy, quadruplet therapy, and the use of multiple lines of treatment...

breast cancer

William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, details the fundamental shift in how clinicians now treat patients with endocrine-sensitive breast cancer, both advanced and early stage, by pairing antihormonal therapy with targeted treatment.

skin cancer
immunotherapy

Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy

Sophia McKinley, MD, EdM, of Massachusetts General Hospital, discusses patterns of recurrence in patients with resected cutaneous melanoma during or after adjuvant immunotherapy. She identifies the risk factors associated with overall survival and treatment failure (Abstract 60).

skin cancer
immunotherapy
issues in oncology

Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma

Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...

breast cancer
issues in oncology

The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer

Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according to a recent report from The Lancet Breast Cancer Commission. These findings were published by Coles...

thyroid cancer

New Findings Suggest No Correlation Between GLP-1 Receptor Agonists and Thyroid Cancer Risk

Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study published by Pasternak et al in the BMJ. Background GLP-1 receptor agonists are designed to reduce blood sugar levels and appetite. They have become...

gynecologic cancers
genomics/genetics

Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections

Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...

skin cancer
issues in oncology

Illuminating a Potential Culprit in Melanoma Treatment Resistance

Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma, according to a recent study published by Aya Moreno et al in Cell Reports. Background The global incidence of melanoma—the deadliest type of skin cancer—is rising, making novel...

lung cancer
issues in oncology

Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers

Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....

bladder cancer
issues in oncology

Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer

Researchers have found that a novel urine biomarker test may effectively halve the number of cystoscopies necessary in high-risk patients with bladder cancer, according to recent findings presented by Dreyer et al at the European Association of Urology (EAU) Congress 2024. The research also...

prostate cancer
issues in oncology

Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients

Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings presented by Albers et al at the European Association of Urology (EAU) Congress 2024 and simultaneously published in European Urology....

prostate cancer
global cancer care

The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040

Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...

skin cancer
immunotherapy

Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy

Jenny H. Chang, MD, of the Cleveland Clinic, discusses the current surgical and radiologic treatment paradigm for patients with stage III Merkel cell carcinoma and the potential for neoadjuvant immunotherapy to help manage the disease and regional lymph node metastases (Abstract 67).

prostate cancer
issues in oncology

Educational Videos May Encourage Prostate Cancer Screening Among Black Patients

Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jones et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

solid tumors
genomics/genetics

BAP1 Mutations May Increase Susceptibility to Asbestos-Induced Malignant Mesothelioma

Researchers have shown that even minimal exposure to chrysotile asbestos may increase susceptibility to the development of malignant mesothelioma in mice with BAP1 germline mutations, according to new findings presented by Kadariya et al at the American Association for Cancer Research (AACR) Annual ...

gynecologic cancers

Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy

Ana Oaknin, MD, PhD, of Spain’s Vall d’Hebron University Hospital, discusses phase III findings from the BEATcc trial, showing that adding atezolizumab to a standard bevacizumab-plus-platinum regimen for patients with metastatic, persistent, or recurrent cervical cancer significantly improves...

pancreatic cancer

An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer

An investigational exosome-based liquid biopsy accurately detected 97% of stage I to II pancreatic cancers when combined with the biomarker CA 19-9, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract 3899). “Pancreatic cancer is one...

prostate cancer
genomics/genetics

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

issues in oncology

AACR Inaugurates New Leadership

The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...

breast cancer
genomics/genetics

PARP1-Selective Inhibitor in HRR-Deficient Breast Cancer

The novel poly-ADP ribose polymerase-1 (PARP1)-selective inhibitor saruparib demonstrated early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancer, according to new findings presented by Yap et al at the American Association for...

head and neck cancer

Investigational Personalized Vaccine in Resected Head and Neck Cancers

TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected human papillomavirus (HPV)-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association...

cns cancers

ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma

AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...

colorectal cancer

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1...

prostate cancer
immunotherapy

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...

pancreatic cancer

Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit

An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...

skin cancer
immunotherapy

RP1 Immunotherapy in Solid Organ Transplant Recipients With Skin Cancer

A novel oncolytic immunotherapy may show antitumor activity in solid organ transplant recipients with skin cancer, according to new findings presented by Migden et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT003). Background "Organ transplant recipients ...

kidney cancer
immunotherapy

Novel CAR T-Cell Therapy May Show Benefit in Patients With Advanced Clear Cell Renal Cell Carcinoma

The CD70-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy CTX130 may be effective in patients with advanced clear cell renal cell carcinoma, according to findings presented by Srour et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract CT002)...

multiple myeloma

Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients With Multiple Myeloma

On April 5, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and...

gynecologic cancers
immunotherapy

Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype

The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...

hepatobiliary cancer
immunotherapy

Can a Personalized Antitumor Vaccine Plus Pembrolizumab Improve Outcomes in Hepatocellular Carcinoma?

Adding a personalized antitumor vaccine to the PD-1 inhibitor pembrolizumab may be safe and about twice as effective at shrinking tumors in patients with hepatocellular carcinoma compared with pembrolizumab alone, according to new findings presented by Yarchoan et al at the American Association for ...

solid tumors

FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors

On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior systemic treatment and have no...

breast cancer

Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer

Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact outcomes, the type of axillary surgery after neoadjuvant chemotherapy does not (Abstract 3).

bladder cancer
immunotherapy
issues in oncology

Improving Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Carcinoma

Two recent studies have offered new insights into the treatment of muscle-invasive urothelial carcinoma following cystectomy, according to findings presented by Powles et al and Galsky et al at the European Association of Urology Congress 2024. The research could allow physicians to target...

colorectal cancer
issues in oncology

Distinct Microbial Signature Uncovered in KRAS-Mutated Colorectal Cancer

Researchers have identified microbiota signatures that are associated with KRAS mutations in patients with colorectal cancer, according to a recent study published by Huang et al in Microbiology Spectrum. The findings suggest that gut microbes may serve as a noninvasive biomarker for subtypes of...

global cancer care
issues in oncology

American Cancer Society Releases Latest Global Cancer Statistics; Cancer Cases Expected to Rise to 35 Million Worldwide by 2050

The American Cancer Society (ACS) has released Global Cancer Statistics 2022, an update of the organization’s report on global cancer facts and trends. According to the findings, an estimated 20 million cancer cases were newly diagnosed in 2022 and 9.7 million people died from the disease...

Danicopan Approved as Add-On Therapy to Ravulizumab or Eculizumab for Extravascular Hemolysis in Adults With Paroxysmal Nocturnal Hemoglobinuria

On April 1, danicopan (Voydeya) was approved by the U.S. Food and Drug Administration (FDA) as add-on therapy to ravulizumab-cwvz or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a first-in-class, oral, Factor D...

lung cancer

Akhil G. Pachimatla, MD, on NSCLC: A Link Between Image-Based Measures of Obesity and Metabolic Pathways

Akhil G. Pachimatla, MD, of Roswell Park Comprehensive Cancer Center, discusses study findings showing that, in patients with non–small cell lung cancer (NSCLC), image-based adiposity measures show stronger correlations with gene-expression changes in these tumors than body mass index measures. Dr. ...

breast cancer

Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy

Kerollos N. Wanis, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses a study in which he evaluated the risk of future ipsilateral and contralateral breast cancer events in a large cohort of patients with BRCA1 or BRCA2 mutations who chose breast conservation (Abstract 12).

leukemia

Feasibility of Ending Specialist Follow-up in Patients With Low-Risk CLL

A study published by Brieghel et al in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, ...

lung cancer
issues in oncology

Study Examines Shared Decision-Making Policies and Practices Around Lung Cancer Screening

A Medicare policy requiring shared decision-making between primary care physicians and patients regarding whether to proceed with lung cancer screening may require further examination, according to a recent study published by Kale et al in the Annals of Family Medicine. The findings indicated that...

solid tumors
issues in oncology
supportive care

Asking ChatGPT About Radiation Oncology Treatment

Researchers examined whether the artificial intelligence (AI)-based chatbot ChatGPT can help provide answers to patients with cancer regarding radiation oncology treatment, according to a recent study published by Yalamanchili et al in JAMA Network Open. Background Over 60% (n = 500,000) of...

issues in oncology

One in Five People With Cancer Participate in Clinical Research, New Study Finds

New findings authored by Joseph M. Unger, PhD, and colleagues in the Journal of Clinical Oncology using Commission on Cancer data showed that when all types of cancer research studies are considered, at least one in five people with cancer in the United States—or 21.9%—participate in some form of...

breast cancer
issues in oncology

Can TILs Help to Determine Outcomes in Triple-Negative Breast Cancer?

High levels of tumor-infiltrating lymphocytes (TILs) within the tumors of patients with early-stage triple-negative breast cancer may be associated with a lower risk of cancer recurrence and greater rate of survival, even without chemotherapy, according to a recent study published by Leon-Ferre et...

Advertisement

Advertisement




Advertisement